Our Story
Our mission: To improve human health and quality of life by transforming the way scientists design therapeutics and materials.
With steadfast investment in R&D, we continue to develop and refine our advanced scientific platform. Our platform is deployed by users worldwide to accelerate research and make novel discoveries that might otherwise not be possible; it is also the foundation of our drug discovery efforts to serve patients with unmet medical needs.
Schrödinger through the years
EXPLORE
1990
Co-founders Richard Friesner and Bill Goddard launch Schrödinger
Co-founders Richard Friesner and Bill Goddard launch Schrödinger
1992
First software sale, to Brookhaven National Laboratory
First software sale, to Brookhaven National Laboratory
1995
First investment from David E. Shaw
First investment from David E. Shaw
2001
Release Glide, which offers high-throughput virtual screening of millions of compounds
Release Glide, which offers high-throughput virtual screening of millions of compounds
2003
Release Prime, a fully integrated protein structure prediction program
Release Prime, a fully integrated protein structure prediction program
2009
Release WaterMap, the first rigorous method for computing protein-bound water locations and energetics
Release WaterMap, the first rigorous method for computing protein-bound water locations and energetics 
Co-found Nimbus Therapeutics with Atlas Venture
2010
First investment from Bill Gates
First investment from Bill Gates 
Launch collaboration with Agios, which will lead to two FDA-approved oncology drugs
2012
Launch Materials Science division
Launch Materials Science division
2014
Release FEP+, the first benchmark method for accurately predicting binding affinity differences among molecules with a common core
Release FEP+, the first benchmark method for accurately predicting binding affinity differences among molecules with a common core 
Release LiveDesign, a next-generation platform for collaborative drug design
2015
Co-found Morphic Therapeutic with Polaris Partners and Tim Springer
Co-found Morphic Therapeutic with Polaris Partners and Tim Springer
2016
Launch collaboration with Sanofi to support drug discovery with computational resources
Launch collaboration with Sanofi to support drug discovery with computational resources 
Gilead acquires Nimbus ACC program for $1.2B
2017
Launch research collaboration with Takeda to accelerate drug discovery
Launch research collaboration with Takeda to accelerate drug discovery
2018
Launch Cyro-EM Initiative to join global research centers in leveraging cryo-electron microscopy
Launch Cyro-EM Initiative to join global research centers in leveraging cryo-electron microscopy Launch collaboration with SPARC to accelerate neurodegeneration drug development
2019
Co-found Faxian Therapeutics drug development company with WuXi AppTec
Co-found Faxian Therapeutics drug development company with WuXi AppTec 
Close $108 million funding round
2020
